

Sengenics launches multi-antigen COVID-19 biochip test

29 June 2020 | News

ImmSAFE™ is a lab-based biochip test that utilises Sengenics' patented KREX™ protein folding technology



Singapore based Sengenics, the Functional Proteomics Company, has announced the launch of ImmSAFE™ COVID+, a multi-antigen, multi-domain, fully quantitative serology test.

ImmSAFE™ enables the determination of the target epitopes, titres and Ig class/sub-class (IgG, IgA, IgM; IgG₁₋₄) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination.

These results will provide critical insights on whether individuals have high titres of potentially neutralising antibodies against SARS-CoV-2 that may protect against reinfection or whether booster vaccinations are required.

ImmSAFE™ COVID+ will also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.

ImmSAFE™ is a lab-based biochip test that utilises Sengenics' patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites.

The test contains more than ten domains of SARS-CoV-2 Nucleocapsid and Spike proteins including full-length and numerous truncated versions.